Progesterone_NN receptors_NNS -_: animal_JJ models_NNS and_CC cell_NN signaling_VBG in_IN breast_NN cancer_NN :_: Progesterone_NN 's_POS role_NN in_IN mammary_JJ gland_NN development_NN and_CC tumorigenesis_NN as_IN disclosed_VBN by_IN experimental_JJ mouse_NN genetics_NNS Abstract_NP |_SYM The_DT progesterone_NN receptor_NN knockout_NN mouse_NN demonstrated_VBD progesterone_NN 's_POS importance_NN to_TO parity-induced_JJ mammary_JJ tertiary_JJ branching_NN and_CC lobuloalveologenesis_NN ._SENT Because_IN early_JJ parity_NN provides_VBZ significant_JJ protection_NN against_IN breast_NN cancer_NN whereas_IN prolonged_JJ exposure_NN to_TO premenopausal_JJ ovarian_JJ progesterone_NN (_( or_CC to_TO postmenopausal_JJ supplementations_NNS thereof_RB )_) has_VBZ been_VBN linked_VBN to_TO breast_VB cancer_NN risk_NN ,_, this_DT steroid_NN can_MD be_VB considered_VBN to_TO exhibit_VB contrasting_VBG roles_NNS in_IN breast_NN cancer_NN etiology_NN ._SENT This_DT review_NN describes_VBZ the_DT important_JJ mouse_NN models_NNS that_WDT have_VBP contributed_VBN to_TO our_PP$ understanding_NN of_IN progesterone_NN 's_POS role_NN in_IN mammary_JJ gland_NN development_NN and_CC neoplasia_NN ._SENT We_PP conclude_VBP by_IN emphasising_VBG the_DT urgent_JJ need_NN to_TO identify_VB the_DT molecular_JJ targets_NNS of_IN the_DT progesterone_NN receptor_NN ,_, and_CC to_TO determine_VB whether_IN these_DT targets_NNS are_VBP modulated_VBN differently_RB by_IN the_DT progesterone_NN receptor_NN isoforms_NNS (_( A_NP and_CC B_NP )_) during_IN mammary_JJ morphogenesis_NN and_CC tumorigenesis_NN ._SENT knockout_JJ ,_, mammary_JJ gland_NN ,_, progesterone_NN ,_, progesterone_NN receptor_NN ,_, tumorigenesis_NN ,_, Epidemiological_JJ studies_NNS have_VBP shown_VBN that_IN early_JJ onset_NN of_IN menarche_NN ,_, delayed_VBN entry_NN into_IN menopause_NN ,_, cycle_NN periodicity_NN ,_, nulliparity_NN ,_, and_CC a_DT late_JJ first_JJ pregnancy_NN represent_VBP individual_JJ risk_NN factors_NNS for_IN breast_NN cancer_NN ._SENT However_RB ,_, early_JJ menopause_NN and_CC early_JJ first_JJ parity_NN decrease_VB this_DT risk_NN ._SENT Because_IN progesterone_NN 's_POS presence_NN or_CC absence_NN directly_RB influences_VBZ the_DT establishment_NN of_IN each_DT of_IN these_DT reproductive_JJ endocrine_JJ states_NNS ,_, assessing_VBG mammary_JJ gland_NN development_NN and_CC tumorigenesis_NN in_IN relation_NN to_TO progesterone_NN exposure_NN is_VBZ of_IN paramount_JJ importance_NN ._SENT As_IN for_IN most_JJS epithelial_JJ cancers_NNS ,_, the_DT incidence_NN of_IN human_JJ breast_NN cancer_NN is_VBZ age_NN dependent_JJ ,_, implicating_VBG a_DT stochastic_JJ multistep_NN progression_NN in_IN the_DT development_NN of_IN this_DT disease_NN ._SENT Although_IN breast_NN cancer_NN incidence_NN increases_NNS with_IN age_NN ,_, the_DT increase_NN is_VBZ not_RB uniform_JJ but_CC achieves_VBZ its_PP$ highest_JJS rate_NN during_IN the_DT reproductive_JJ years_NNS of_IN premenopause_NN ._SENT The_DT data_NNS suggest_VBP that_IN ovarian_JJ steroidal_JJ exposure_NN of_IN the_DT mammary_JJ epithelial_JJ cell_NN (_( MEC_NP )_) during_IN this_DT reproductive_JJ period_NN underlies_VBZ the_DT risk_NN to_TO breast_NN cancer_NN presented_VBN by_IN many_JJ of_IN the_DT aforementioned_JJ reproductive_JJ endocrine_JJ states_NNS ._SENT One_CD hypothesis_NN to_TO account_VB for_IN the_DT link_NN between_IN ovarian_JJ steroidal_JJ exposure_NN and_CC human_JJ breast_NN cancer_NN risk_NN is_VBZ that_IN ovarian_JJ steroid-induced_JJ MEC_NP proliferation_NN provides_VBZ a_DT temporal_JJ window_NN of_IN opportunity_NN for_IN the_DT progressive_JJ acquisition_NN of_IN genetic_JJ errors_NNS ._SENT As_IN a_DT result_NN of_IN these_DT errors_NNS ,_, the_DT transformed_VBN MEC_NP is_VBZ predicted_VBN to_TO undergo_VB unchecked_JJ clonal_JJ expansion_NN to_TO a_DT mammary_JJ neoplasm_NN ._SENT Although_IN estrogen_NN 's_POS proliferative_JJ effects_NNS on_IN mammary_JJ gland_NN development_NN and_CC tumorigenesis_NN are_VBP well_RB recognized_VBN ,_, progesterone_NN 's_POS contribution_NN to_TO these_DT processes_NNS has_VBZ been_VBN mired_VBN in_IN controversy_NN ._SENT Much_RB of_IN this_DT controversy_NN has_VBZ been_VBN exacerbated_VBN in_IN the_DT past_NN by_IN :_: first_RB ,_, our_PP$ inability_NN to_TO mechanistically_RB dissect_VB the_DT individual_JJ roles_NNS of_IN estrogen_NN and_CC progesterone_NN in_IN vivo_JJ ;_: second_JJ ,_, progesterone_NN 's_POS established_JJ inhibitory_JJ role_NN on_IN estrogen-induced_JJ luminal_JJ epithelial_JJ proliferation_NN in_IN the_DT uterus_NN ,_, and_CC the_DT extrapolation_NN of_IN this_DT inhibitory_JJ role_NN to_TO the_DT mammary_JJ gland_NN ;_: and_CC third_JJ ,_, the_DT increasing_VBG number_NN of_IN conflicting_JJ reports_NNS concerning_VBG the_DT importance_NN of_IN synthetic_JJ progestins_NNS in_IN mammary_JJ tumor_NN progression_NN in_IN the_DT rodent_NN ._SENT The_DT acknowledged_JJ gaps_NNS in_IN our_PP$ understanding_NN concerning_VBG progesterone_NN 's_POS involvement_NN in_IN human_JJ breast_NN cancer_NN has_VBZ exposed_VBN the_DT urgent_JJ need_NN to_TO better_RBR understand_VB the_DT role_NN played_VBN by_IN progesterone_NN as_IN an_DT endocrine_JJ mammogen_NN in_IN normal_JJ mammary_JJ gland_NN development_NN ._SENT In_IN the_DT present_JJ review_NN ,_, we_PP provide_VBP an_DT overview_NN of_IN how_WRB experimental_JJ mouse_NN genetics_NN has_VBZ not_RB only_RB defined_VBN progesterone_NN 's_POS unique_JJ contribution_NN to_TO mammary_JJ gland_NN morphogenesis_NN and_CC function_NN ,_, but_CC has_VBZ also_RB aided_VBN in_IN the_DT formulation_NN of_IN new_JJ concepts_NNS concerning_VBG the_DT role_NN of_IN this_DT ovarian_JJ steroid_NN in_IN the_DT normal_JJ and_CC neoplastic_JJ development_NN of_IN this_DT tissue_NN ._SENT Postnatal_JJ mammary_JJ gland_NN development_NN |_SYM The_DT mouse_NN as_IN an_DT experimental_JJ tool_NN of_IN inquiry_NN |_SYM Because_IN many_JJ of_IN the_DT fundamental_JJ aspects_NNS of_IN mammary_JJ gland_NN development_NN and_CC tumorigenesis_NN are_VBP conserved_VBN between_IN rodents_NNS and_CC humans_NNS ,_, the_DT rodent_NN model_NN (_( in_IN particular_JJ ,_, the_DT rat_NN and_CC the_DT mouse_NN )_) has_VBZ historically_RB served_VBN as_IN the_DT experimental_JJ system_NN of_IN choice_NN for_IN in_IN vivo_JJ mammary_JJ gland_NN research_NN ._SENT With_IN the_DT recent_JJ advent_NN of_IN powerful_JJ genetic_JJ approaches_NNS to_TO manipulate_VB the_DT murine_JJ genome_NN ,_, the_DT mouse_NN offers_VBZ an_DT unprecedented_JJ level_NN of_IN sophistication_NN with_IN which_WDT to_TO query_VB systemic_JJ or_CC locally_RB acting_VBG hormonal_JJ controls_NNS on_IN mammogenesis_NN ,_, from_IN the_DT genetic_JJ ,_, cellular_JJ ,_, and_CC molecular_JJ perspectives_NNS ._SENT As_RB with_IN the_DT human_JJ ,_, murine_JJ postnatal_JJ mammary_JJ gland_NN development_NN consists_VBZ of_IN two_CD distinct_JJ allometric_JJ growth_NN stages_NNS ._SENT The_DT first_JJ of_IN these_DT stages_NNS occurs_VBZ at_IN the_DT onset_NN of_IN puberty_NN ,_, whereas_IN the_DT second_JJ manifests_NNS in_IN response_NN to_TO pregnancy_NN ._SENT At_IN puberty_NN ,_, in_IN response_NN to_TO systemic_JJ estrogen_NN and_CC locally_RB acting_VBG growth_NN factors_NNS ,_, cap_NN cells_NNS of_IN terminal_JJ end_NN buds_NNS undergo_VBP extensive_JJ mitosis_NN to_TO drive_VB ductal_JJ elongation_NN and_CC dichotomous_JJ branching_VBG to_TO the_DT limits_NNS of_IN the_DT fat_JJ pad_NN ._SENT On_IN reaching_VBG adulthood_NN ,_, the_DT mammary_JJ gland_NN is_VBZ growth_NN quiescent_JJ except_IN for_IN incipient_JJ side_NN branching_NN and_CC alveolar_JJ budding_JJ (_( conspicuous_JJ in_IN most_JJS strains_NNS ,_, but_CC not_RB all_RB )_) ,_, which_WDT develop_VBP over_IN time_NN as_IN a_DT result_NN of_IN the_DT exposure_NN of_IN the_DT tissue_NN to_TO cycling_NN levels_NNS of_IN ovarian_JJ steroids_NNS ._SENT Figure_NP 1_CD |_SYM Progesterone_NP receptor_NN function_NN is_VBZ required_VBN for_IN mammary_JJ ductal_JJ side-branching_NN and_CC alveologenesis_NN ._SENT Progesterone_NN receptor_NN function_NN is_VBZ required_VBN for_IN mammary_JJ ductal_JJ side-branching_NN and_CC alveologenesis_NN ._SENT (_( a_DT )_) The_DT salient_JJ postnatal_JJ stages_NNS of_IN mammary_JJ gland_NN development_NN ._SENT Whole_JJ mounts_NNS of_IN (_( b_LS )_) transplanted_JJ progesterone_NN receptor_NN knockout_NN (_( PRKO_NP )_) mammary_JJ glands_NNS and_CC (_( c_LS )_) wild-type_JJ mammary_JJ glands_NNS taken_VBN from_IN a_DT nulliparous_JJ host_NN ,_, and_CC (_( d_LS )_) transplanted_VBN PRKO_NP mammary_JJ glands_NNS and_CC (_( e_LS )_) wild-type_JJ mammary_JJ glands_NNS taken_VBN from_IN a_DT parous_JJ host_NN ._SENT Scale_NN bar_NN in_IN (_( b_LS )_) denotes_VBZ 500_CD m_NN and_CC applies_VBZ to_TO all_DT whole_JJ mounts_NNS ._SENT Adapted_VBN from_IN Lydon_NP et_FW al._FW ._SENT In_IN response_NN to_TO the_DT hormones_NNS of_IN pregnancy_NN ,_, the_DT epithelial_JJ compartment_NN of_IN the_DT mammary_JJ gland_NN undergoes_VBZ proliferation_NN and_CC subsequent_JJ differentiation_NN to_TO generate_VB alveoli_NNS that_WDT progressively_RB fill_VBP the_DT interductal_JJ spaces_NNS during_IN late_JJ pregnancy_NN ,_, parturition_NN ,_, and_CC lactation_NN ._SENT Following_VBG weaning_VBG ,_, removal_NN of_IN the_DT suckling_NN stimulus_NN triggers_VBZ collapse_NN of_IN the_DT lobuloalveolar_JJ system_NN through_IN proteinase-mediated_JJ and_CC apoptotic-mediated_JJ reductive_JJ remodeling_NN processes_NNS ,_, collectively_RB termed_VBN involution_NN ._SENT On_IN completion_NN of_IN involution_NN ,_, the_DT reinstatement_NN of_IN the_DT mammary_JJ gland_NN to_TO a_DT ductal_JJ architecture_NN resembling_VBG the_DT mammary_JJ phenotype_NN of_IN the_DT prepregnant_JJ mouse_NN completes_VBZ the_DT cycle_NN of_IN development_NN ._SENT Importantly_RB ,_, epidemiological_JJ and_CC experimental_JJ investigations_NNS have_VBP provided_VBN irrefutable_JJ evidence_NN that_IN completion_NN of_IN this_DT developmental_JJ cycle_NN early_RB in_IN the_DT reproductive_JJ life_NN in_IN rat_NN ,_, mouse_NN and_CC human_JJ species_NN confers_VBZ a_DT significant_JJ protection_NN against_IN breast_NN cancer_NN in_IN later_JJR life_NN ._SENT However_RB ,_, this_DT protection_NN is_VBZ lost_VBN with_IN a_DT late_JJ first_JJ pregnancy_NN ._SENT Given_VBN that_IN the_DT stage_NN of_IN mammary_JJ gland_NN development_NN at_IN the_DT time_NN of_IN carcinogen_NN exposure_NN greatly_RB influences_VBZ subsequent_JJ breast_NN cancer_NN initiation_NN and_CC progression_NN ,_, experimental_JJ mouse_NN genetics_NN has_VBZ recently_RB been_VBN applied_VBN to_TO delineate_VB progesterone_NN 's_POS role_NN in_IN the_DT elaboration_NN of_IN each_DT of_IN these_DT developmental_JJ stages_NNS ._SENT The_DT progesterone_NN receptor_NN knockout_JJ mouse_NN |_SYM The_DT progesterone_NN receptor_NN |_SYM Most_JJS of_IN the_DT physiological_JJ effects_NNS of_IN progesterone_NN are_VBP mediated_VBN by_IN its_PP$ intracellular_JJ receptor_NN ,_, the_DT progesterone_NN receptor_NN (_( PR_NP )_) ,_, which_WDT is_VBZ a_DT member_NN of_IN the_DT nuclear_JJ receptor_NN superfamily_NN of_IN transcription_NN factors_NNS ._SENT On_IN binding_JJ progesterone_NN ligand_NN ,_, the_DT nuclear_JJ receptor_NN ligand_NN complex_NN translocates_VBZ to_TO the_DT nucleus_NN to_TO induce_VB or_CC to_TO silence_VB the_DT expression_NN of_IN downstream_JJ target_NN genes_NNS ,_, which_WDT in_IN turn_NN manifest_VBP the_DT physiological_JJ response_NN of_IN the_DT target_NN cell_NN to_TO the_DT hormone_NN ,_, progesterone_NN ._SENT In_IN most_JJS physiological_JJ systems_NNS ,_, including_VBG the_DT mammary_JJ gland_NN ,_, the_DT PR_NP is_VBZ induced_VBN by_IN estrogen_NN ,_, through_IN its_PP$ cognate_JJ nuclear_JJ receptor_NN :_: the_DT estrogen_NN receptor_NN ._SENT The_DT PR_NP comprises_VBZ two_CD isoforms_NNS ,_, PR-A_NP and_CC PR-B_NP ,_, which_WDT are_VBP expressed_VBN from_IN the_DT same_JJ gene_NN and_CC are_VBP structurally_RB identical_JJ except_IN for_IN a_DT short_JJ amino_NN acid_NN extension_NN contained_VBN in_IN the_DT N-terminal_JJ region_NN of_IN PR-B_NP ._SENT Previous_JJ transient_JJ transfection_NN experiments_NNS demonstrated_VBD that_IN the_DT two_CD PR_NP isoforms_NNS exhibit_VBP distinct_JJ transactivational_JJ functions_NNS ,_, which_WDT are_VBP dependent_JJ on_IN the_DT cell_NN of_IN origin_NN and_CC on_IN the_DT target_NN gene_NN promoter_NN context_NN ._SENT Specifically_RB ,_, in_IN cell_NN types_NNS in_IN which_WDT PR-A_NP is_VBZ inactive_JJ ,_, the_DT PR-B_NN isoform_NN (_( in_IN the_DT absence_NN of_IN PR-A_NP )_) is_VBZ a_DT strong_JJ transactivator_NN of_IN several_JJ PR-regulated_JJ promoters_NNS ._SENT In_IN a_DT physiological_JJ setting_NN ,_, these_DT results_NNS suggest_VBP that_IN the_DT PR-A_NP and_CC PR-B_NP isoforms_NNS may_MD regulate_VB distinct_JJ sets_NNS of_IN target_NN genes_NNS and_CC may_MD exhibit_VB different_JJ transactivational_JJ capabilities_NNS in_IN a_DT given_VBN progesterone-responsive_JJ target_NN tissue_NN ._SENT Moreover_RB ,_, in_IN cell_NN and_CC promoter_NN contexts_NNS in_IN which_WDT PR-A_NP lacks_VBZ transactivational_JJ activity_NN ,_, the_DT coexpression_NN of_IN PR-A_NP and_CC PR-B_NP demonstrated_VBD that_IN the_DT PR-A_NP isoform_NN could_MD act_VB as_IN a_DT dominant_JJ repressor_NN of_IN PR-B_NN activity_NN ._SENT In_IN a_DT cellular_JJ context_NN in_IN which_WDT PR-A_NP and_CC PR-B_NP are_VBP coexpressed_VBN ,_, this_DT observation_NN suggests_VBZ that_IN PR-A_NP has_VBZ the_DT ability_NN to_TO attenuate_VB the_DT general_JJ progesterone_NN responsiveness_NN of_IN specific_JJ PR_NP target_NN genes_NNS in_IN specific_JJ target_NN tissues_NNS in_IN vivo_RB ._SENT Characterization_NN of_IN the_DT progesterone_NN receptor_NN knockout_JJ mouse_NN |_SYM To_TO directly_RB examine_VB the_DT physiological_JJ significance_NN of_IN PR_NP function_NN in_IN the_DT murine_JJ mammary_JJ gland_NN ,_, a_DT progesterone_NN receptor_NN knockout_NN (_( PRKO_NP )_) mouse_NN model_NN was_VBD generated_VBN in_IN which_WDT both_DT PR_NP isoforms_NNS were_VBD simultaneously_RB abrogated_VBN through_IN gene_NN targeting_VBG approaches_NNS ._SENT Initial_JJ phenotypic_JJ characterization_NN of_IN the_DT PRKO_NP mouse_NN revealed_VBD that_DT removal_NN of_IN PR_NP function_NN resulted_VBD in_IN a_DT spectrum_NN of_IN reproductive_JJ abnormalities_NNS in_IN the_DT female_NN ,_, which_WDT included_VBD severe_JJ endocrine_JJ defects_NNS ,_, an_DT intrinsic_JJ impairment_NN in_IN ovulation_NN ,_, a_DT dysfunctional_JJ uterus_NN ,_, and_CC a_DT loss_NN in_IN mating_VBG behaviors_NNS ._SENT Unlike_IN the_DT estrogen_NN receptor-alpha_NN knockout_NN mouse_NN ,_, in_IN which_WDT the_DT absence_NN of_IN estrogen_NN signaling_VBG resulted_VBN in_IN a_DT block_NN in_IN mammary_JJ ductal_JJ outgrowth_NN at_IN puberty_NN ,_, the_DT PRKO_NP mouse_NN mammary_JJ gland_NN exhibited_VBD normal_JJ ductal_JJ elongation_NN to_TO generate_VB a_DT simple_JJ ductal_JJ architecture_NN that_WDT was_VBD morphologically_RB similar_JJ to_TO the_DT mammary_JJ gland_NN of_IN the_DT young_JJ wild-type_NN virgin_NN ._SENT Together_RB ,_, the_DT estrogen_NN receptor-alpha_NN knockout_NN and_CC PRKO_NP mouse_NN models_NNS highlight_VB the_DT specific_JJ importance_NN of_IN ovarian_JJ estrogen_NN rather_RB than_IN progesterone_NN in_IN epithelial_JJ ductal_JJ elongation_NN in_IN the_DT pubescent_JJ mammary_JJ gland_NN ._SENT To_TO address_VB whether_IN the_DT progesterone_NN signal_NN is_VBZ requisite_JJ for_IN the_DT observed_JJ increase_NN in_IN ductal_JJ side_NN branching_NN and_CC lateral_JJ alveolar_NN budding_VBG in_IN the_DT cycling_NN nulliparous_JJ mouse_NN ,_, as_RB well_RB as_IN for_IN the_DT observed_JJ morphological_JJ responses_NNS to_TO the_DT full_JJ spectrum_NN of_IN pregnancy_NN hormones_NNS in_IN the_DT parous_JJ mouse_NN ,_, PRKO_NP MECs_NP were_VBD transplanted_VBN into_IN the_DT cleared_VBN mammary_JJ fat_JJ pad_NN of_IN a_DT wild-type_NN host_NN ._SENT The_DT whole_JJ mammary_JJ gland_NN transplantation_NN approach_NN was_VBD necessary_JJ to_TO circumvent_VB the_DT inherent_JJ infertility_NN defect_NN of_IN the_DT PRKO_NP mouse_NN ._SENT In_IN the_DT case_NN of_IN the_DT cycling_NN nulliparous_JJ host_NN ,_, the_DT absence_NN of_IN ductal_JJ side_NN branching_NN and_CC lateral_JJ alveolar_NN budding_VBG in_IN glands_NNS containing_VBG transplanted_JJ PRKO_NP MECs_NP as_RB compared_VBN with_IN transplanted_JJ wild-type_NN MECs_NP supports_VBZ a_DT role_NN for_IN progesterone_NN in_IN ovarian_JJ hormone-driven_JJ mammary_JJ epithelial_JJ cell_NN proliferation_NN ._SENT As_IN indicated_VBN in_IN the_DT Introduction_NN ,_, ovarian_JJ steroidal-induced_JJ mammary_JJ epithelial_JJ proliferation_NN has_VBZ been_VBN implicated_VBN as_IN a_DT basis_NN for_IN nulliparity-associated_JJ breast_NN cancer_NN risk_NN ._SENT Indeed_RB ,_, the_DT recent_JJ utilization_NN of_IN the_DT PRKO_NP mouse_NN in_IN combination_NN with_IN the_DT chemical_JJ carcinogen-induced_JJ mammary_JJ tumor_NN model_NN demonstrated_VBD the_DT critical_JJ role_NN that_IN progesterone-induced_JJ mammary_JJ epithelial_JJ proliferation_NN can_MD play_VB in_IN the_DT initiation_NN and_CC progression_NN of_IN carcinogen-induced_JJ mammary_JJ tumors_NNS ._SENT As_IN a_DT corollary_NN to_TO the_DT aforementioned_JJ PRKO_NP mammary_JJ tumor_NN studies_NNS ,_, recent_JJ investigations_NNS have_VBP indicated_VBN that_IN progesterone_NN may_MD also_RB facilitate_VB chromosomal_JJ instability_NN (_( aneuploidy_NN )_) in_IN the_DT subsequent_JJ stages_NNS of_IN mammary_JJ tumor_NN progression_NN that_WDT follow_VBP the_DT loss_NN of_IN p53_NN function_NN ._SENT In_IN the_DT parous_JJ host_NN ,_, despite_IN exposure_NN to_TO the_DT hormonal_JJ milieu_NN of_IN pregnancy_NN ,_, transplanted_VBD PRKO_NP MECs_NP failed_VBD to_TO elicit_VB further_RBR ductal_JJ side-branching_NN and_CC lobuloalveologenesis_NN ,_, as_RB observed_VBN with_IN transplanted_JJ wild-type_NN MECs_NNS ._SENT Because_IN early_JJ parity_NN provides_VBZ significant_JJ protection_NN against_IN breast_NN cancer_NN in_IN later_JJR life_NN ,_, understanding_VBG the_DT cellular_JJ and_CC molecular_JJ mechanisms_NNS by_IN which_WDT progesterone_NN exerts_VBZ these_DT pregnancy-associated_JJ morphological_JJ and_CC functional_JJ changes_NNS in_IN the_DT mammary_JJ gland_NN is_VBZ now_RB an_DT important_JJ priority_NN for_IN contemporary_JJ mammary_JJ gland_NN research_NN ._SENT To_TO address_VB this_DT issue_NN ,_, recent_JJ studies_NNS have_VBP provided_VBN convincing_JJ evidence_NN that_WDT progesterone_NN (_( with_IN estrogen_NN )_) exerts_VBZ a_DT pivotal_JJ role_NN in_IN the_DT elaboration_NN of_IN persistent_JJ molecular_JJ changes_NNS (_( i.e._FW the_DT activation_NN of_IN p53-signaling_NN pathways_NNS )_) in_IN a_DT subgroup_NN of_IN mammary_JJ epithelial_JJ cells_NNS that_WDT may_MD contribute_VB to_TO parity-induced_JJ protection_NN against_IN mammary_JJ cancer_NN ._SENT Indeed_RB ,_, elegant_JJ studies_NNS recently_RB reported_VBD by_IN Wagner_NP et_FW al._FW suggest_VBP that_IN these_DT parity-induced_JJ mammary_JJ epithelial_JJ populations_NNS may_MD be_VB identified_VBN and_CC isolated_VBN in_IN the_DT near_JJ future_NN ._SENT Future_JJ directions_NNS |_SYM A_DT paracrine_JJ mode_NN of_IN action_NN |_SYM As_IN in_IN the_DT human_JJ mammary_JJ gland_NN ,_, immunohistochemical_JJ studies_NNS on_IN the_DT murine_JJ mammary_JJ gland_NN have_VBP demonstrated_VBN that_IN PR_NP expression_NN is_VBZ restricted_VBN to_TO the_DT luminal_JJ epithelial_JJ cell_NN ._SENT Importantly_RB ,_, recent_JJ immunofluorescence_NN experiments_NNS have_VBP revealed_VBN that_IN the_DT majority_NN of_IN epithelial_JJ cells_NNS ,_, which_WDT undergo_VBP proliferation_NN in_IN response_NN to_TO progesterone_NN ,_, are_VBP segregated_VBN from_IN ,_, but_CC in_IN close_JJ apposition_NN to_TO ,_, PR-positive_JJ cells_NNS ._SENT These_DT observations_NNS support_VBP a_DT paracrine_JJ mode_NN of_IN action_NN in_IN which_WDT PR-positive_JJ cells_NNS (_( in_IN response_NN to_TO progesterone_NN )_) express_VB and_CC secrete_VB a_DT paracrine_NN mediator(s)_NN that_WDT impacts_VBZ a_DT neighboring_JJ PR-negative_JJ cell_NN to_TO proliferate_VB ._SENT Interestingly_RB ,_, a_DT paracrine_JJ mode_NN of_IN action_NN for_IN progesterone_NN has_VBZ also_RB been_VBN shown_VBN to_TO exist_VB in_IN the_DT uterus_NN ._SENT Unlike_IN the_DT mammary_JJ gland_NN ,_, however_RB ,_, the_DT progesterone-induced_JJ paracrine_NN circuit_NN emanates_VBZ from_IN the_DT uterine_JJ stromal_JJ compartment_NN to_TO influence_VB luminal_JJ epithelial_JJ proliferation_NN ._SENT Figure_NP 2_CD |_SYM Paracrine_JJ mode_NN of_IN action_NN for_IN progesterone-induced_JJ branching_VBG morphogenesis_NN in_IN the_DT mammary_JJ gland_NN ._SENT Paracrine_JJ mode_NN of_IN action_NN for_IN progesterone-induced_JJ branching_VBG morphogenesis_NN in_IN the_DT mammary_JJ gland_NN ._SENT (_( a_DT )_) Indirect_NN immunofluorescence_NN analysis_NN of_IN a_DT rat_NN mammary_JJ gland_NN shows_VBZ luminal_JJ epithelial_JJ cells_NNS expressing_VBG the_DT progesterone_NN receptor_NN (_( PR_NP )_) (_( red_JJ )_) or_CC undergoing_VBG proliferation_NN (_( green_JJ )_) as_IN measured_VBN by_IN 5-bromo-deoxyuridine_NP ._SENT The_DT arrow_NN indicates_VBZ a_DT single_JJ proliferating_VBG cell_NN (_( yellow_JJ )_) ,_, which_WDT also_RB expresses_VBZ the_DT PR_NP ._SENT Scale_NN bar_NN represents_VBZ 50_CD m._NN (_( b_LS )_) All_DT nuclei_NNS in_IN the_DT field_NN shown_VBN in_IN (_( a_DT )_) ,_, as_RB detected_VBN by_IN 6-diamidino-2-phenylindole_JJ incorporation_NN ._SENT Details_NNS of_IN this_DT experiment_NN are_VBP described_VBN elsewhere_RB ._SENT (_( c_LS )_) The_DT conceptual_JJ idea_NN of_IN a_DT paracrine_JJ mode_NN of_IN action_NN for_IN progesterone_NN in_IN mammary_JJ branching_NN morphogenesis_NN ._SENT '_'' X_NP '_POS denotes_VBZ the_DT elusive_JJ downstream_JJ paracrine_NN mediator(s)_NN of_IN the_DT progesterone_NN (_( P4_NP )_) proliferative_JJ signal_NN ._SENT Adapted_VBN from_IN Lydon_NP et_FW al._FW ._SENT The_DT finding_NN that_IN the_DT nonuniform_JJ cellular_JJ organization_NN pattern_NN for_IN PR-positive_JJ cells_NNS and_CC proliferating_VBG PR-negative_JJ cells_NNS is_VBZ conserved_VBN between_IN the_DT human_JJ mammary_JJ gland_NN and_CC the_DT rodent_NN mammary_JJ gland_NN has_VBZ provided_VBN strong_JJ support_NN for_IN an_DT evolutionary_JJ conserved_VBN cellular_JJ mechanism_NN of_IN action_NN by_IN which_WDT PR-positive_JJ cells_NNS influence_VBP neighboring_JJ PR-negative_JJ cells_NNS to_TO participate_VB in_IN ductal_JJ morphogenesis_NN ._SENT Although_IN the_DT reasons_NNS for_IN such_PDT an_DT evolutionary_JJ conserved_VBN nonuniform_JJ cellular_JJ organization_NN for_IN PR_NP expression_NN is_VBZ uncertain_JJ ,_, derailment_NN of_IN such_PDT an_DT important_JJ cellular_JJ arrangement_NN is_VBZ predicted_VBN to_TO adversely_RB affect_VB normal_JJ mammary_JJ gland_NN development_NN ._SENT Indeed_RB ,_, in_IN the_DT case_NN of_IN many_JJ steroid_NN receptor_NN positive_JJ human_JJ breast_NN tumors_NNS ,_, the_DT majority_NN of_IN estrogen_NN and_CC progesterone_NN receptor_NN positive_JJ tumor_NN cells_NNS also_RB undergo_VBP proliferation_NN ,_, clearly_RB contravening_VBG the_DT paracrine_NN signaling_VBG circuit_NN that_WDT exists_VBZ in_IN the_DT normal_JJ gland_NN ._SENT Although_IN speculative_JJ ,_, the_DT above_JJ studies_NNS suggest_VBP that_IN the_DT genesis_NN of_IN these_DT tumors_NNS may_MD require_VB an_DT early_JJ switch_NN in_IN steroid-dependent_JJ regulation_NN of_IN proliferation_NN from_IN a_DT paracrine_NN to_TO an_DT autocrine_NN mechanism_NN ._SENT Additional_JJ support_NN for_IN the_DT importance_NN of_IN this_DT cellular_JJ organization_NN pattern_NN for_IN PR_NP expression_NN to_TO normal_JJ mammary_JJ gland_NN development_NN comes_VBZ from_IN the_DT recent_JJ analysis_NN of_IN the_DT adult_JJ CCAAT/enhancer_NP binding_JJ protein_NN beta_NN knockout_NN mammary_JJ gland_NN ,_, which_WDT does_VBZ not_RB respond_VB to_TO the_DT proliferative_JJ effects_NNS of_IN estrogen_NN and_CC progesterone_NN ._SENT In_IN contrast_NN to_TO a_DT nonuniform_JJ cellular_JJ distribution_NN pattern_NN for_IN PR_NP expression_NN observed_VBD in_IN the_DT normal_JJ gland_NN ,_, the_DT CCAAT/enhancer_NP binding_JJ protein_NN beta_NN knockout_NN mammary_JJ gland_NN exhibits_VBZ a_DT uniform_JJ cellular_JJ organization_NN pattern_NN for_IN PR-positive_JJ cells_NNS with_IN the_DT attendant_JJ absence_NN of_IN PR-negative_JJ cells_NNS that_WDT proliferate_VBP in_IN response_NN to_TO the_DT progesterone_NN paracrine_NN signal_NN ._SENT Clearly_RB ,_, to_TO gain_VB a_DT more_RBR meaningful_JJ mechanistic_JJ understanding_NN of_IN progesterone_NN 's_POS paracrine_NN mode_NN of_IN action_NN in_IN the_DT mammary_JJ gland_NN ,_, identification_NN of_IN the_DT downstream_JJ genetic_JJ networks_NNS that_WDT relay_VBP the_DT progesterone_NN signal_NN will_MD be_VB essential_JJ ._SENT Towards_IN this_DT end_NN ,_, recent_JJ studies_NNS have_VBP provided_VBN strong_JJ evidence_NN that_IN the_DT wnt-4_NN signaling_VBG pathway_NN may_MD act_VB as_IN an_DT important_JJ paracrine_NN mediator_NN of_IN the_DT progesterone-initiated_JJ proliferative_JJ signal_NN in_IN the_DT mammary_JJ gland_NN ._SENT With_IN the_DT availability_NN of_IN the_DT complete_JJ murine_JJ genome_NN sequence_NN ,_, of_IN gene_NN discovery_NN approaches_NNS ,_, and_CC of_IN genetic_JJ strategies_NNS to_TO conditionally_RB turn_VB on_RP or_CC turn_VB off_RP potential_JJ target_NN genes_NNS in_IN the_DT murine_JJ mammary_JJ gland_NN ,_, we_PP anticipate_VBP that_DT progesterone_NN 's_POS mammogenic_JJ effects_NNS will_MD be_VB readily_RB exposed_VBN to_TO molecular_JJ dissection_NN in_IN the_DT near_JJ future_NN ._SENT PR-A_NP and_CC PR-B_NP |_SYM Transgenic_NP approaches_NNS have_VBP recently_RB been_VBN employed_VBN to_TO address_VB whether_IN the_DT PR_NP isoforms_NNS (_( PR-A_NP and_CC PR-B_NP )_) mediate_VBP distinct_JJ physiological_JJ effects_NNS in_IN the_DT mammary_JJ gland_NN ._SENT Overexpression_NN of_IN PR-A_NP resulted_VBD in_IN increased_VBN ductal_JJ branching_NN and_CC eventual_JJ hyperplasia_NN ,_, whereas_IN PR-B_NN overexpression_NN caused_VBD reduced_VBN ductal_JJ elongation_NN and_CC branching_NN ._SENT These_DT in_IN vivo_JJ investigations_NNS strongly_RB support_VBP the_DT concept_NN that_IN progesterone_NN 's_POS physiological_JJ signal_NN is_VBZ interpreted_VBN differently_RB by_IN its_PP$ two_CD receptor_NN isoforms_NNS ,_, and_CC that_DT misexpression_NN of_IN either_RB one_CD of_IN these_DT isoforms_NNS can_MD result_VB in_IN aberrant_JJ mammary_JJ gland_NN development_NN ._SENT Using_VBG gene_NN targeting_VBG approaches_NNS ,_, a_DT specific_JJ knockout_NN for_IN the_DT PR-A_NP isoform_NN (_( PRAKO_NP )_) has_VBZ recently_RB been_VBN generated_VBN and_CC characterized_VBN ._SENT The_DT PRAKO_NP mouse_NN ,_, like_IN the_DT PRKO_NP mouse_NN ,_, exhibited_VBD a_DT infertility_NN phenotype_NN ._SENT Unlike_IN the_DT PRKO_NP mouse_NN ,_, however_RB ,_, the_DT PRAKO_NP mammary_JJ gland_NN developed_VBN normally_RB in_IN the_DT absence_NN of_IN PR-A_NP function_NN ._SENT Although_IN PR-A_NP is_VBZ expressed_VBN in_IN the_DT mammary_JJ gland_NN ,_, these_DT studies_NNS suggest_VBP that_IN ,_, unlike_IN most_RBS other_JJ progesterone_NN target_NN tissues_NNS ,_, the_DT PR-B_NN isoform_NN may_MD functionally_RB compensate_VB for_IN PR-A_NP in_IN the_DT murine_JJ mammary_JJ gland_NN ._SENT To_TO determine_VB whether_IN PR-B_NN is_VBZ indispensable_JJ for_IN mammary_JJ development_NN or_CC whether_IN its_PP$ actions_NNS can_MD be_VB compensated_VBN by_IN PR-A_NP ,_, a_DT specific_JJ knockout_NN for_IN the_DT PR-B_NN isoform_NN (_( PRBKO_NP )_) mouse_NN model_NN has_VBZ recently_RB been_VBN generated_VBN and_CC is_VBZ currently_RB being_VBG characterized_VBN ._SENT Unlike_IN the_DT PRAKO_NP mouse_NN ,_, the_DT PRBKO_NP female_NN is_VBZ fertile_JJ ._SENT Initial_JJ mammary_JJ gland_NN studies_NNS ,_, however_RB ,_, indicate_VBP that_DT loss_NN of_IN PR-B_NN function_NN results_NNS in_IN reduced_VBN pregnancy-associated_JJ ductal_JJ branching_NN compared_VBN with_IN wild-type_JJ mammary_JJ glands_NNS (_( Conneely_NP OM_NP ,_, unpublished_JJ data_NNS ,_, 2002_CD )_) ._SENT These_DT data_NNS ,_, although_IN preliminary_JJ ,_, suggest_VBP that_IN most_JJS of_IN the_DT mammogenic_JJ effects_NNS of_IN progesterone_NN are_VBP mediated_VBN by_IN the_DT PR-B_NN isoform_NN in_IN the_DT mouse_NN ._SENT Experimental_JJ mouse_NN genetics_NN has_VBZ highlighted_VBN progesterone_NN 's_POS indispensable_JJ role_NN in_IN pregnancy-induced_JJ morphological_JJ and_CC functional_JJ changes_NNS in_IN the_DT mammary_JJ gland_NN ._SENT If_IN the_DT aforementioned_JJ developmental_JJ changes_NNS occur_VBP early_RB in_IN reproductive_JJ life_NN ,_, a_DT significant_JJ protection_NN against_IN breast_NN cancer_NN can_MD be_VB achieved_VBN ._SENT Because_IN prolonged_JJ progesterone_NN exposure_NN ,_, either_CC through_IN uninterrupted_JJ cyclical_JJ ovarian_JJ activity_NN or_CC by_IN postmenopausal_JJ supplementation_NN ,_, has_VBZ been_VBN linked_VBN to_TO breast_VB cancer_NN risk_NN ,_, progesterone_NN can_MD be_VB viewed_VBN as_IN an_DT endocrine_JJ mammogen_NN with_IN contrasting_VBG roles_NNS with_IN respect_NN to_TO breast_VB cancer_NN etiology_NN ._SENT With_IN this_DT view_NN in_IN mind_NN ,_, our_PP$ concepts_NNS of_IN breast_NN cancer_NN risk_NN in_IN relation_NN to_TO progesterone_NN exposure_NN will_MD remain_VB just_RB that_IN until_IN the_DT downstream_JJ genetic_JJ pathways_NNS through_IN which_WDT progesterone_NN affects_VBZ normal_JJ and_CC neoplastic_JJ mammary_JJ development_NN are_VBP identified_VBN ._SENT With_IN the_DT availability_NN of_IN PRKO_NP mouse_NN models_NNS for_IN PR-A_NP ,_, PR-B_NP or_CC both_DT isoforms_NNS ,_, in_IN combination_NN with_IN DNA_NP microarray_NN approaches_NNS ,_, we_PP believe_VBP this_DT goal_NN will_MD soon_RB be_VB realized_VBN ._SENT MEC_NN =_SYM mammary_JJ epithelial_JJ cell_NN ;_: PR_NP =_SYM progesterone_NN receptor_NN ;_: PRAKO_NP =_SYM a_DT specific_JJ knockout_NN for_IN the_DT PR-A_NP isoform_NN ;_: PRBKO_NP =_SYM a_DT specific_JJ knockout_NN for_IN the_DT PR-B_NN isoform_NN ;_: PRKO_NP =_SYM progesterone_NN receptor_NN knockout_NN ._SENT 